This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Investors' Inferiority Complex

Making a larger run at the oil and gas service sector makes perfect sense for GE, said Cramer. Already the company is leading the way with natural gas locomotives, turbines and lot more. Lufkin will be a perfect fit, he said, but there are still other opportunities for GE to acquire.

Cramer suggested FMC Technology (FTI), currently valued at $12 billion, could be one company that could complement GE's investments and cement its place in the industry. Chart Industries (GTLS), along with Clean Harbors (CLH) and Core Labs (CLB) are other possibilities.

Cramer reminded viewers that he never recommends a stock on a takeover unless the fundamentals are also strong. In all of these cases, these stocks can make investors a lot of money as oil and gas in America rages on.

Pharma Focus on J&J

After spending the past two weeks highlighting companies in the biotech space, Cramer said he didn't want to give the impression that old-line Big Pharma doesn't have opportunities,too.

So he has kicked off a week-long series starting with Johnson & Johnson (JNJ), a stock Cramer owns for his charitable trust, Action Alerts PLUS .

With its 3.3% yield, Cramer said J&J is a magnet for international money looking for safety. While the company received a downgrade today, Cramer thinks the report was shortsighted because the company is worth a lot more than the analysts realize.

While Wall Street likes companies that are easy to understand, J&J has become messy, with many different divisions that are begging to be broken up to unlock their true value, Cramer said. Wall Street likes things that are simple; hopefully, J&J can deliver on that front soon.

The Johnson & Johnson Achilles heel has been the company's consumer products division, which has been plagued by issues and recalls. But that division is beginning to clean itself up, said Cramer, while at the same time J&J's pharma division has past its "patent cliff" where many of its biggest drugs lost patent protection.

Cramer said the company still has a strong pipeline of new drugs, including three in Phase III testing. He recommended buying in after earnings, but ahead of J&J's scheduled pipeline review set for May 23.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs